Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
Sponsor: Mirati Therapeutics Inc.
Sponsor score: 40
ClinicalTrials ID:NCT05609578
Study CA239-0010 is a Phase 2 trial assessing adagrasib with pembrolizumab and chemotherapy in advanced NSCLC patients with KRAS G12C mutation. Eligible participants have TPS ≥ 1% and TPS < 50%. Interventions include oral adagrasib (400 mg twice daily) and IV infusions of pembrolizumab, pemetrexed, and cisplatin/carboplatin every three weeks.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS <50% and KRAS G12C mutation
Eligibility Criteria
Exclusion Criteria
- All Cohorts: Any prior therapy targeting KRASG12C mutation in any setting
- Cohorts A & E: Prior systemic therapy for locally advanced or metastatic NSCLC, including chemotherapy, immune checkpoint inhibitor therapy or chemoimmunotherapy (note: prior systemic therapy or chemoradiation given in the adjuvant or neoadjuvant setting are allowed if last dose of prior systemic treatment was >1 year prior to first dose of study treatment)
- Cohort C: received maintenance therapy (e.g, pembrolizumab and/or pemetrexed following completion of 4-6 cycles of a platinum-based regimen administered in the first-line setting
- Radiation to the lung > 30 Gy within 6 months prior to first dose of study treatment
- Active brain metastases
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| Local Institution - Unk025 | 99508 | Anchorage | Alaska |
| Local Institution - 017-591 | 85304 | Glendale | Arizona |
| Local Institution - 017-821 | 85004 | Phoenix | Arizona |
| Local Institution - Unk047 | 92805 | Anaheim | California |
| Local Institution - 017-936C | 92708 | Fountain Valley | California |
| MemorialCare - Orange Coast Medical Center | 92708 | Fountain Valley | California |
| Providence Medical Foundation - Virginia K. Crosson Cancer Center - Fullerton | 92835 | Fullerton | California |
| Local Institution - Unk004 | 92354 | Loma Linda | California |
| Local Institution - 017-961 | 90095 | Los Angeles | California |
| UCSF Helen Diller Family Comprehensive Cancer Center | 94158 | San Francisco | California |
Get This Program In Your Inbox
You can sign up and apply your patients for this program.